In its most recent 13F filing, Commerzbank Aktiengesellschaft FI disclosed a 30.5% reduction in its position in AbbVie during the third quarter, selling 39,586 shares and ending the period with 90,102 shares valued at $20.86 million. Other institutions also adjusted their holdings: Norges Bank initiated a new stake worth approximately $4.29 billion; Laurel Wealth Advisors increased its position to over 5.7 million shares (valued at $1.06 billion); Vanguard Group added 3.38 million shares, bringing its total to 177.3 million shares ($32.91 billion); DZ BANK AG more than doubled its stake to 4.72 million shares ($876.66 million); and Raymond James Financial boosted its holdings by 41.8% to 9.34 million shares ($1.73 billion). Institutional investors and hedge funds now own 70.23% of AbbVie’s shares.

AbbVie reported third-quarter adjusted EPS of $1.86, $0.09 above consensus, on revenue of $15.78 billion, beating the $15.58 billion consensus and representing a 9.1% year-over-year increase. The company’s net margin stood at 4.0%, and return on equity reached 3,216%. Management announced a quarterly dividend of $1.73 per share, up from $1.64, implying an annualized payout of $6.92 and a yield of roughly 3.2%. AbbVie maintained guidance for full-year EPS in the range of $3.32–$3.36 and analysts currently forecast 12.31 EPS for the upcoming year.